Safety and Efficacy of BHV-3000 (Rimegepant) Orally Disintegrating Tablet for the Acute Treatment of Chronic Rhinosinusitis

PHASE3CompletedINTERVENTIONAL
Enrollment

261

Participants

Timeline

Start Date

February 17, 2022

Primary Completion Date

March 11, 2024

Study Completion Date

April 2, 2024

Conditions
Chronic Rhinosinusitis (CRS) With and Without Nasal Polyps
Interventions
DRUG

rimegepant 75 mg ODT

One dose of rimegepant 75 mg ODT

DRUG

Matching placebo

One dose of matching placebo

Trial Locations (33)

11042

Northwell Health Department of Otolaryngology, New Hyde Park

29118

Carolina ENT Clinic/CENTRI Inc., Orangeburg

29621

Velocity Clinical Research, Anderson, Anderson

32132

Velocity Clinical Research, New Smyrna Beach, Edgewater

33021

The Medici Medical Research, LLC, Hollywood

33064

Clinovation Research, Pompano Beach

33155

Avantis Clinical Research, Miami

40205

Kentuckiana Ear, Nose & Throat, Louisville

53228

Allergy, Asthma & Sinus Center, S.C., Greenfield

60657

ChicagoENT, Chicago

63304

St Charles Clinical Research, Weldon Spring

65201

University of Missouri Hospital & Clinics, ENT & Allergy Center of Missouri, Columbia

65212

University of Missouri Healthcare - Investigational Pharmacy, Columbia

University of Missouri Hospital (Radiology), Columbia

65810

Clinvest Research, LLC, Springfield

70115

Best Clinical Trials, LLC (Administrative Only), New Orleans

George Stanley Walker, MD, New Orleans

73013

Tekton Research, Inc., Edmond

73120

Allergy, Asthma & Clinical Research Center, Oklahoma City

74136

Vital Prospects Clinical Research Institute, P.C., Tulsa

80923

Colorado ENT & Allergy, Colorado Springs

83706

Treasure Valley Medical Research, Boise

90503

Breathe Clear Institute, Torrance

91402

National Research Institute, Panorama City

91942

San Diego Clinical Research Center, La Mesa

Velocity Clinical San Diego, La Mesa

92123

Sharp & Children's MRI Center, LLC (CT scan), San Diego

95628

Sacramento Ear Nose and Throat Surgical and Medical Group, Inc., Roseville

97504

Velocity Clinical Research, Medford, Medford

97527

Velocity Clinical Research, Grants Pass, Grants Pass

99201

Spokane Ear, Nose & Throat/ Columbia Surgical Specialists, Spokane

99204

Principle Research Solutions, Spokane

99216

Spokane Ear, Nose & Throat / Columbia Surgical Specialists, Spokane

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Pfizer

INDUSTRY

NCT05248997 - Safety and Efficacy of BHV-3000 (Rimegepant) Orally Disintegrating Tablet for the Acute Treatment of Chronic Rhinosinusitis | Biotech Hunter | Biotech Hunter